UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and HighlightsGlobeNewsWire • 11/04/26
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceGlobeNewsWire • 11/03/26
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder CancerGlobeNewsWire • 11/02/26
UroGen's Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial CancerGlobeNewsWire • 10/28/26
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026GlobeNewsWire • 10/27/26
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBCGlobeNewsWire • 10/19/26
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in FocusZacks Investment Research • 09/08/26
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/04/26
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a BetZacks Investment Research • 08/21/26
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology TherapiesPRNewsWire • 08/20/26
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology PipelineGlobeNewsWire • 08/20/26
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBCGlobeNewsWire • 08/17/26
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great ChoiceZacks Investment Research • 08/14/26